

Funder	Project Title	Funding	Institution
Brain & Behavior Research Foundation	Enhancing Social Learning Through Oxytocin Augmentation of Social Skills Groups in Children with ASD	\$0	Rush University
Brain & Behavior Research Foundation	Rebuilding Inhibition in the Autistic Brain	\$24,840	Brandeis University
Brain & Behavior Research Foundation	Mechanism-based Treatment Targets and Biomarkers for Genetically Defined Mental Illnesses	\$25,000	Cincinnati Children's Hospital Medical Center
Brain & Behavior Research Foundation	Modulation of the Oxytocin System in a Mouse Model of Autism Spectrum Disorder (ASD)	\$16,079	University of the Basque Country
Department of Defense - Army	Treating Gastrointestinal and Autism Symptoms in Adults with Autism Using Microbiota Transfer Therapy (MTT)	\$0	Arizona State University
Department of Defense - Army	Development of Novel Drugs Targeting Serotonin Receptors to Treat Motor, Social, Cognitive, and Sensory Domains of Autism Spectrum Disorder Using Mouse Models	\$0	Mercer University
Department of Defense - Army	Neurosteroids Reverse Tonic Inhibition Deficits in Fragile X Syndrome	\$0	Tufts University School of Medicine
Department of Defense - Army	Neurosteroids Reverse Tonic Inhibition Deficits in Fragile X Syndrome	\$0	Tufts University School of Medicine
Department of Defense - Army	Development of Novel Drugs Targeting Serotonin Receptors to Treat Motor, Social, Cognitive, and Sensory Domains of Autism Spectrum Disorder Using Mouse Models	\$0	Northeastern University
Department of Defense - Army	Sulforaphane Treatment of Children with Autism Spectrum Disorder (ASD)	\$0	University of Massachusetts Medical School
Department of Defense - Army	Trial of Propranolol in Children and Youth with ASD and Predictors of Response	\$0	University of Missouri
Department of Defense - Army	Cannabidiol (CBD) Versus Placebo in Children with Autism Spectrum Disorder (ASD)	\$0	Albert Einstein College of Medicine
Autism Research Institute	Clinical Trial of Suramin to Treat Autism	\$0	University of California, San Diego Medical Center
Autism Research Institute	Clinical Trial of Suramin to Treat Autism	\$5,317	University of California, San Diego Medical Center
Autism Research Institute	Mitochondrial Dysfunction Associated with Autism: Clinical Signals and Treatment Outcomes	\$0	Boston University
Autism Research Institute	To study CREB and Akt after zinc therapy	\$6,600	Hartwick College
Autism Science Foundation	Screening for new autism treatments using cells in a dish	\$35,000	University of California, San Diego
Autism Science Foundation	A Unified Molecular Mechanism Explaining Social Behavior and Oxytocin levels in ASD	\$0	Washington University in St. Louis
Autism Science Foundation	Combined Effects of Early Behavioral Intervention and Propranolol on ASD	\$0	University of Missouri
Autism Science Foundation	The Effects of Oxytocin on Functional Neural Connectivity in Autism	\$0	Univ of North Carolina, Chapel Hill
Autism Speaks	Response Heterogeneity to GI Treatment, Autism Symptom and Improved Oxidative Stress	\$413,989	Children's Hospital Los Angeles
Autism Speaks	Nicotinic cholinergic modulation as a novel treatment strategy for aggression associated with autism	\$61,600	Yale University

Funder	Project Title	Funding	Institution
Autism Speaks	PACT contract	\$202,999	Boston Children's Hospital
Autism Speaks	Identifying Genetic and Epigenetic Signatures of Treatment Response to Oxytocin in Humans and Mice	\$30,400	Duke University
Health Resources and Services Administration	A Controlled Trial of Sertraline in Young Children with ASD	\$0	University of California, Davis
Health Resources and Services Administration	Autism Intervention Research Network on Physical Health (AIR-P network)	\$874,678	Massachusetts General Hospital
Health Resources and Services Administration	Investigation of Teacher-Mediated Toilet Training Using a Manualized Moisture Alarm Intervention	\$0	University of Rochester Medical Center
National Institutes of Health	Preventing Epilepsy Using Vigabatrin in Infants with Tuberous Sclerosis Complex	\$1,730,358	University of Alabama at Birmingham
National Institutes of Health	A High-Dose Folinic Acid Treatment for Core and Associated Symptoms of Autism	\$668,729	Arkansas Children's Hospital Res Inst
National Institutes of Health	Proof of Mechanism Study for the Treatment of Social Anhedonia in ASD	\$262,210	University of California, Los Angeles
National Institutes of Health	Specifying and Treating the Anxiety Phenotype in Autism Spectrum Disorder	\$629,602	University of California, Davis
National Institutes of Health	Intranasal Vasopressin Treatment in Children with Autism	\$630,656	Stanford University
National Institutes of Health	Novel Therapy for Fragile X Syndrome	\$399,938	Epigen Biosciences, Inc.
National Institutes of Health	Novel Therapy for Fragile X Syndrome	\$117,346	Epigen Biosciences, Inc.
National Institutes of Health	4/5-The Autism Biomarkers Consortium for Clinical Trials	\$816,582	Yale University
National Institutes of Health	Data Coordinating Core	\$826,868	Yale University
National Institutes of Health	5/5-The Autism Biomarkers Consortium for Clinical Trials	\$899,317	Yale University
National Institutes of Health	1/5-The Autism Biomarkers Consortium for Clinical Trials	\$899,591	Yale University
National Institutes of Health	3/5-The Autism Biomarkers Consortium for Clinical Trials	\$902,523	Yale University
National Institutes of Health	2/5-The Autism Biomarkers Consortium for Clinical Trials	\$1,159,872	Yale University
National Institutes of Health	Administrative Core	\$1,277,792	Yale University
National Institutes of Health	Data Acquisition and Analysis Core	\$1,719,292	Yale University
National Institutes of Health	Regulation of 22q11 Genes in Embryonic and Adult Forebrain	\$445,484	George Washington University
National Institutes of Health	Preclinical Imaging of Adolescent Cannabidiol on Brain Structure and Functional Connectivity	\$76,250	University of Florida
National Institutes of Health	The Effects of Intranasal Oxytocin on Social Cognition and Neural Activity	\$610,993	Emory University
National Institutes of Health	Integrated Treatments for Core Deficits in Autism Spectrum Disorder	\$146,796	Rush University Medical Center
National Institutes of Health	Postnatal Combination Therapy for Cerebral Palsy	\$333,841	Johns Hopkins University

Funder	Project Title	Funding	Institution
National Institutes of Health	Neurobiology of pain and behavior changes associated with rare diseases and developmental disabilities	\$75,000	NIH Clinical Center
National Institutes of Health	Neuromodulation Treatment for Self-Injurious Behavior Associated with Intellectual and Developmental Disabilities	\$204,427	Johns Hopkins University
National Institutes of Health	Behavioral and Neural Response to Memantine in Adolescents with Autism	\$196,992	Massachusetts General Hospital
National Institutes of Health	Rapid, in Vitro Phenotyping of Monogenic Neurological Disorders Using CRISPRi and High-Throughput All-Optical Electrophysiology.	\$345,471	Q-State Biosciences, Inc.
National Institutes of Health	Development of Roralpha and Rorgamma Ligands for Treatment of Behavioral Disorders	\$595,993	Saint Louis University
National Institutes of Health	Prefrontal Function in the Shank3-Deficient Rat: a First Rat Model for ASD	\$457,912	Icahn School of Medicine at Mount Sinai
National Institutes of Health	Discovery of Novel Drugs for Autism	\$388,482	Asddr, Llc
National Institutes of Health	Impact of Combined Medication and Behavioral Treatment in Young Children with Comorbid ASD and ADHD	\$477,000	Duke University
National Institutes of Health	Fatty Acid Supplements Alter Biological Signatures in Children with Autism Spectrum Disorder	\$327,066	Nationwide Children's Hospital
National Institutes of Health	PTP1B Inhibitors for the Treatment of Rett Syndrome	\$258,746	Case Western Reserve University
Simons Foundation	Autism synaptic endophenotypes & candidate drug rescue	\$75,000	Stanford University
Simons Foundation	Randomized Controlled Pilot Trial of Pregnenolone in Autism	\$125,000	Stanford University
Simons Foundation	Synthetic Infrared Nanosensors for Real-time Monitoring of Oxytocin Release	\$69,986	The Regents of the University of California, Berkeley
Simons Foundation	A probiotic therapy for autism	\$125,000	California Institute of Technology
Simons Foundation	Neural circuitry linking oxytocin deficiency and social impairment in ASD	\$150,000	University of California, Los Angeles
Simons Foundation	Detecting and Treating Social Impairments in a Monkey Model	\$322,894	Stanford University
Simons Foundation	Modulation of mitochondrial efficiency to treat Fragile X Syndrome	\$72,631	Yale University
Simons Foundation	Translating Neuroprediction into Precision Medicine via Brain Priming - Core	\$97,225	Yale University
Simons Foundation	High-throughput drug discovery in zebrafish models of ASD risk genes	\$62,500	Yale University
Simons Foundation	Translating Neuroprediction into Precision Medicine via Brain Priming - Project 1	\$80,535	The George Washington University
Simons Foundation	Clinical Research Associates	\$2,130,000	Clinical Research Associates

Funder	Project Title	Funding	Institution
Simons Foundation	Safety, Efficacy and Basis of Oxytocin and Brain Stimulation Therapy in ASD	\$95,140	University of Pennsylvania
Simons Foundation	Evaluation of a melanocortin agonist to improve social cognition in autism	\$0	University of Sydney
Simons Foundation	Regulation of KCC2 as a target for treatment of Autism	\$224,999	University Laval
Simons Foundation	Modulation of a splicing regulatory network commonly disrupted in autism	\$75,000	Governing Council of the University of Toronto
Simons Foundation	BKCa channels openers for the treatment of sensory hypersensitivity in ASD	\$0	Institut National de la Santé et de la Recherche Médicale-ADR-Bordeaux
National Science Foundation	US Ignite: Focus Area 1: A Networked Virtual Reality Platform for Immersive Online Social Learning of Youth with Autism Spectrum Disorders	\$0	University of Missouri
The New England Center for Children	A behavioral analysis of anxiety in children with autism	\$5,750	The New England Center for Children
FRAXA Research Foundation (FRAXA)	Combinatorial Drug Treatment in a Model of Fragile X Syndrome using Novel Biomarkers	\$90,000	University of California at Riverside
FRAXA Research Foundation (FRAXA)	Novel Modulators of Potassium Channels to Treat Fragile X	\$161,000	Yale University
FRAXA Research Foundation (FRAXA)	NKCC1 Inhibitor Bumetanide Corrects Synaptic and Circuit Hyperexcitability in Fragile X Mouse Model	\$258,000	Northwestern University
FRAXA Research Foundation (FRAXA)	Mechanisms of Tolerance to Chronic mGluR5 Inhibition	\$90,000	Massachusetts Institute of Technology (MIT)
FRAXA Research Foundation (FRAXA)	Fragile X Clinical Trial of AZD7325 in Adults	\$51,000	Cincinnati Children's Hospital
FRAXA Research Foundation (FRAXA)	A Kinase Assay as a Biomarker for Fragile X Syndrome	\$90,000	University of Antwerp
FRAXA Research Foundation (FRAXA)	Lovamix: Clinical Trial of Combined Treatment of Minocycline and Lovastatin in Fragile X Syndrome	\$66,714	Université de Sherbrooke
FRAXA Research Foundation (FRAXA)	Repurposing Study II: Evaluating Combinations of Drugs to Treat Fragile X	\$47,500	Healx
FRAXA Research Foundation (FRAXA)	Enhancement of NMDA Receptor Signaling for the Treatment of Fragile X Syndrome	\$90,000	University of Edinburgh

